<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK3789" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK3789/" /><meta name="ncbi_pagename" content="CDC73-Related Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>CDC73-Related Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="CDC73-Related Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/04/26" /><meta name="citation_author" content="Samuel M Hyde" /><meta name="citation_author" content="Thereasa A Rich" /><meta name="citation_author" content="Steven G Waguespack" /><meta name="citation_author" content="Nancy D Perrier" /><meta name="citation_author" content="Mimi I Hu" /><meta name="citation_pmid" content="20301744" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK3789/" /><meta name="citation_keywords" content="Hyperparathyroidism-Jaw Tumor Syndrome" /><meta name="citation_keywords" content="Familial Isolated Hyperparathyroidism" /><meta name="citation_keywords" content="Parathyroid Carcinoma" /><meta name="citation_keywords" content="Parafibromin" /><meta name="citation_keywords" content="CDC73" /><meta name="citation_keywords" content="CDC73-Related Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="CDC73-Related Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Samuel M Hyde" /><meta name="DC.Contributor" content="Thereasa A Rich" /><meta name="DC.Contributor" content="Steven G Waguespack" /><meta name="DC.Contributor" content="Nancy D Perrier" /><meta name="DC.Contributor" content="Mimi I Hu" /><meta name="DC.Date" content="2018/04/26" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK3789/" /><meta name="description" content="The spectrum of CDC73-related disorders includes the following phenotypes:" /><meta name="og:title" content="CDC73-Related Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="The spectrum of CDC73-related disorders includes the following phenotypes:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK3789/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hrpt2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK3789/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE899CB9E04121910000000003F101B2.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK3789_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK3789_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/catsper-mi/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cdk13-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK3789_"><span class="title" itemprop="name"><i>CDC73</i>-Related Disorders</span></h1><p class="contrib-group"><span itemprop="author">Samuel M Hyde</span>, MMSc, CGC, <span itemprop="author">Thereasa A Rich</span>, MS, CGC, <span itemprop="author">Steven G Waguespack</span>, MD, <span itemprop="author">Nancy D Perrier</span>, MD, FACS, and <span itemprop="author">Mimi I Hu</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK3789_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK3789_ai__"><div class="contrib half_rhythm"><span itemprop="author">Samuel M Hyde</span>, MMSc, CGC<div class="affiliation small">Certified Genetic Counselor, Clinical Cancer Genetics<br />The University of Texas MD Anderson Cancer Center<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.nosrednadm@edyhms" class="oemail">gro.nosrednadm@edyhms</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Thereasa A Rich</span>, MS, CGC<div class="affiliation small">Certified Genetic Counselor, Clinical Cancer Genetics<br />The University of Texas MD Anderson Cancer Center<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@hcirasaereht" class="oemail">moc.liamg@hcirasaereht</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Steven G Waguespack</span>, MD<div class="affiliation small">Professor, Department of Endocrine Neoplasias and Hormonal Disorders Department of Pediatrics<br />The University of Texas MD Anderson Cancer Center<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.nosrednadm@seugaws" class="oemail">gro.nosrednadm@seugaws</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Nancy D Perrier</span>, MD, FACS<div class="affiliation small">Professor, Department of Surgical Oncology<br />The University of Texas MD Anderson Cancer Center<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.nosrednadm@reirrepn" class="oemail">gro.nosrednadm@reirrepn</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mimi I Hu</span>, MD<div class="affiliation small">Associate Professor, Department of Endocrine Neoplasias and Hormonal Disorders<br />The University of Texas MD Anderson Cancer Center<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.nosrednadm@uhm" class="oemail">gro.nosrednadm@uhm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 31, 2008</span>; Last Update: <span itemprop="dateModified">April 26, 2018</span>.</p><p><em>Estimated reading time: 34 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hrpt2.Summary" itemprop="description"><h2 id="_hrpt2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The spectrum of <i>CDC73</i>-related disorders includes the following phenotypes:</p><ul><li class="half_rhythm"><div><i>Hyperparathyroidism-jaw tumor (HPT-JT) syndrome.</i> Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome.</div></li><li class="half_rhythm"><div><i>Parathyroid carcinoma.</i> Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, non-functioning parathyroid carcinomas are also rarely described in individuals with a <i>CDC73-</i>related disorder. A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in 20%-29% of individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> parathyroid carcinoma.</div></li><li class="half_rhythm"><div><i>Familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism (FIHP).</i> FIHP is characterized by primary hyperparathyroidism without other associated <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> features. Individuals with <i>CDC73-</i>related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The optimal surgical approach to primary hyperparathyroidism in HPT-JT syndrome has not yet been established; however, because many individuals with HPT-JT syndrome present with a single benign parathyroid tumor, a minimally invasive approach to remove the abnormal parathyroid gland followed by close monitoring for recurrent primary hyperparathyroidism has been suggested. If parathyroid carcinoma is clinically suspected (large tumor on imaging, palpable neck mass, severe presentation of primary hyperparathyroidism), an <i>en bloc</i> resection of the parathyroid gland with surrounding, adherent tissue and the ipsilateral thyroid lobe should be considered. Cinacalcet hydrochloride has been approved for the treatment of severe hypercalcemia secondary to primary hyperparathyroidism in individuals who are unable to undergo parathyroidectomy and for the treatment of parathyroid carcinoma-related hypercalcemia. Jaw tumors should be treated surgically as indicated by size, location, and symptoms; the treatment of choice is complete resection, which may not be possible in all individuals. Renal and uterine manifestations are managed on a case-by-case basis.</p><p><i>Prevention of secondary complications:</i> Decrease the risk of postoperative hypoparathyroidism: ensure normal preoperative 25-(OH) vitamin D concentration; recognize risk factors for hungry bone syndrome, such as an elevated alkaline phosphatase level; postoperative monitoring with replacement of calcium and vitamin D. Minimize postoperative nausea and vomiting to prevent devascularization of the remaining in situ parathyroid glands. Avoid biopsy of extrathyroidal tissue to reduce the risk of seeding of a parathyroid carcinoma. Consider <i>en bloc</i> resection in those with suspected parathyroid carcinoma to optimize a surgical cure and prevent positive surgical margins or seeding of parathyroid tissue (parathyromatosis) during removal.</p><p><i>Surveillance:</i> Starting at age five years, serum calcium, intact parathyroid hormone (iPTH), and 25-(OH) vitamin D levels annually, and dental panoramic x-ray with neck shielding at least every five years starting at age ten. Renal ultrasound examination at least every five years, starting at the age of diagnosis. For women, starting at reproductive age, lifelong monitoring for uterine tumors with routine gynecologic care and pelvic ultrasound examination as clinically indicated.</p><p><i>Agents/circumstances to avoid:</i> Dehydration; radiation exposure; biopsy of extrathyroidal tissue in the neck, which increases the risk of seeding of parathyroid tissue.</p><p><i>Evaluation of relatives at risk:</i> If the family-specific <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk relatives should be offered starting around age five years in order to identify as early as possible those who would benefit from initiation of surveillance, treatment, and/or preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>CDC73</i>-related disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. An individual with a <i>CDC73</i>-related disorder may have inherited the disorder from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent or developed it as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of <i>CDC73</i>. The proportion of individuals with a <i>de novo</i> pathogenic variant is unknown. Each child of an individual with a <i>CDC73</i>-related disorder has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the <i>CDC73</i> pathogenic variant in the family is known.</p></div></div><div id="hrpt2.GeneReview_Scope"><h2 id="_hrpt2_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="hrpt2.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3789/table/hrpt2.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hrpt2.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hrpt2.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDC73</i>-Related Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_hrpt2.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism</div></li><li class="half_rhythm"><div>Hyperparathyroidism-jaw tumor syndrome</div></li><li class="half_rhythm"><div>Parathyroid carcinoma</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#hrpt2.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="hrpt2.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes, see <a href="#hrpt2.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="hrpt2.Diagnosis"><h2 id="_hrpt2_Diagnosis_">Diagnosis</h2><p>The diagnosis of a <i>CDC73</i>-related disorder requires a thorough personal and family history as well as <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Given the <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> and <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> associated with certain <i>CDC73</i> pathogenic variants, the resulting <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> can differ, and the identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CDC73</i> should be interpreted in the right clinical context in order to establish the most accurate phenotype. No formal diagnostic criteria for <i>CDC73-</i>related disorders have been published. There is currently no published genetic testing algorithm.</p><div id="hrpt2.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>CDC73</i>-related disorders <b>should be suspected</b> in individuals with any of the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Primary hyperparathyroidism and ossifying fibroma(s) of the jaw</div></li><li class="half_rhythm"><div class="half_rhythm">Primary hyperparathyroidism with young-onset (age &#x0003c;45 years) disease and cystic, atypical, and/or malignant parathyroid histology</div></li><li class="half_rhythm"><div class="half_rhythm">Childhood- or adolescent-onset primary hyperparathyroidism</div></li><li class="half_rhythm"><div class="half_rhythm">Childhood-onset ossifying fibroma(s) of the maxilla or mandible</div><div class="half_rhythm">Note: The frequency of <i>CDC73</i> pathogenic variants in individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ossifying fibromas of the jaw appears low [<a class="bk_pop" href="#hrpt2.REF.chen.2016.91">Chen et al 2016</a>]; however, this has not been extensively studied (see <a href="#hrpt2.Clinical_Characteristics">Clinical Characteristics</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">Primary hyperparathyroidism with absence of nuclear parafibromin staining in parathyroid tumor as demonstrated by immunohistochemistry</div></li><li class="half_rhythm"><div class="half_rhythm">Primary hyperparathyroidism or ossifying jaw fibroma and a personal or family history of HPT-JT-associated conditions, such as Wilms tumor or other genitourinary disease</div></li><li class="half_rhythm"><div class="half_rhythm">Familial primary hyperparathyroidism and absence of:</div><ul><li class="half_rhythm"><div>Features of a <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> cause of primary hyperparathyroidism (e.g., multiple endocrine neoplasia type 1 [MEN1])</div></li><li class="half_rhythm"><div>MEN1 (confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>)</div></li></ul></li></ul><p><b>Laboratory features of primary hyperparathyroidism</b></p><ul><li class="half_rhythm"><div>Elevated total calcium corrected for albumin (preferred) or ionized calcium</div></li><li class="half_rhythm"><div>Elevated or inappropriately normal intact parathyroid hormone (iPTH)</div></li></ul><p><b>Radiographic features of ossifying fibromas.</b> Panoramic x-ray and/or a classic mandibular series reveals mandibular or maxillary well-circumscribed lesions that are often, but not always, radiolucent and expand the underlying bone. Note: (1) Sporadic mandibular ossifying fibromas tend to appear as mixed radiolucent/radiopaque lesions [<a class="bk_pop" href="#hrpt2.REF.aldred.2006.212">Aldred et al 2006</a>]. (2) The panoramic x-ray interpretation must be correlated with clinical and, in some individuals, tissue examination. X-rays of this type should be interpreted by someone familiar with the variables of anatomy and nuances of the panoramic x-ray.</p><p><b>Histopathologic features of resected parathyroid lesions</b></p><ul><li class="half_rhythm"><div>Parathyroid carcinoma</div></li><li class="half_rhythm"><div>Atypical parathyroid adenoma</div></li><li class="half_rhythm"><div>Parathyroid adenoma with or without cystic features</div></li><li class="half_rhythm"><div>Loss of parafibromin expression</div></li></ul></div><div id="hrpt2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of a <i>CDC73</i>-related disorder is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. <i>CDC73</i>-related disorders include three clinically and genetically overlapping entities:</p><ul><li class="half_rhythm"><div>A diagnosis of <b>hyperparathyroidism-jaw tumor (HPT-JT) syndrome</b> is established in individuals with a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and any of the following clinical features:</div><ul><li class="half_rhythm"><div>Primary hyperparathyroidism AND ossifying fibroma(s) of the maxilla and/or mandible</div></li><li class="half_rhythm"><div>Primary hyperparathyroidism AND a close relative with HPT-JT syndrome</div></li><li class="half_rhythm"><div>Ossifying fibroma(s) of the maxilla and/or mandible AND a close relative with HPT-JT syndrome</div></li></ul></li><li class="half_rhythm"><div>A diagnosis of <b><i>CDC73</i>-related parathyroid carcinoma</b> is established in individuals with parathyroid carcinoma and a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and no family history suggestive of a <i>CDC73</i>-related disorder (<a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case). <i>CDC73</i> pathogenic variants have been found in individuals with clinically nonfamilial (apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>) parathyroid carcinoma and parathyroid adenoma.</div></li><li class="half_rhythm"><div>A diagnosis of <b><i>CDC73</i>-related <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism (FIHP)</b> is established in individuals with primary hyperparathyroidism and a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who have at least one close relative with primary hyperparathyroidism in the absence of ossifying fibromas. Primary hyperparathyroidism in these families could be caused by parathyroid carcinoma.</div></li></ul><p>It is important to obtain regular personal and family history updates in individuals with <i>CDC73</i> pathogenic variants, as changes in these histories could also change which <i>CDC73</i>-related disorder is the most accurate diagnosis.</p><p><b>Molecular genetic testing</b> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Many laboratories may only offer concurrent <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>. However, if a tiered testing approach is available, it is reasonable to consider performing sequence analysis of <i>CDC73</i> first, followed by gene-targeted deletion/duplication analysis if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found by sequence analysis.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CDC73</i> and other genes of interest (see <a href="#hrpt2.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> varies by laboratory and over time. (2) Some multigene panels may include genes not associated with the conditions discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK3789/table/hrpt2.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighrpt2Tmoleculargenetictestingusedi" rid-ob="figobhrpt2Tmoleculargenetictestingusedi">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="hrpt2.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>CDC73</i>-Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3789/table/hrpt2.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hrpt2.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDC73</i></td><td headers="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;70%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_hrpt2.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;30%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hrpt2.TF.1.1"><p class="no_margin">See <a href="/books/NBK3789/#hrpt2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hrpt2.TF.1.2"><p class="no_margin">See <a href="#hrpt2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hrpt2.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hrpt2.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#hrpt2.REF.iacobone.2009.817">Iacobone et al [2009]</a>, <a class="bk_pop" href="#hrpt2.REF.newey.2010">Newey et al [2010]</a>, <a class="bk_pop" href="#hrpt2.REF.panicker.2010.513">Panicker et al [2010]</a>, <a class="bk_pop" href="#hrpt2.REF.rekik.2010.121">Rekik et al [2010]</a>, <a class="bk_pop" href="#hrpt2.REF.wang.2010.1694">Wang et al [2010]</a>, <a class="bk_pop" href="#hrpt2.REF.cavaco.2011.44">Cavaco et al [2011]</a>, <a class="bk_pop" href="#hrpt2.REF.frankraue.2011.477">Frank-Raue et al [2011]</a>, <a class="bk_pop" href="#hrpt2.REF.pichardolowden.2011.602">Pichardo-Lowden et al [2011]</a>, <a class="bk_pop" href="#hrpt2.REF.siu.2011.695">Siu et al [2011]</a>, <a class="bk_pop" href="#hrpt2.REF.starker.2012.44">Starker et al [2012]</a>, <a class="bk_pop" href="#hrpt2.REF.bricaire.2013.e403">Bricaire et al [2013]</a>, <a class="bk_pop" href="#hrpt2.REF.kutcher.2013.e175">Kutcher et al [2013]</a></p></div></dd><dt>5. </dt><dd><div id="hrpt2.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="hrpt2.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#hrpt2.REF.bricaire.2013.e403">Bricaire et al [2013]</a>; complete <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>CDC73</i> has been reported (see <a href="#hrpt2.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd></dl></div></div></div><p>Sporadic tumors (including parathyroid carcinoma, benign parathyroid tumors, and renal tumors) occurring as single tumors in the absence of any other findings of a <i>CDC73</i>-related disorder may harbor somatic variants in <i>CDC73</i> that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable; however, germline testing should still be performed if a <i>CDC73-</i>associated disorder is suspected clinically, as somatic testing is not suitable for identifying or excluding hereditary disease. For more details, see <a href="#hrpt2.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div></div><div id="hrpt2.Clinical_Characteristics"><h2 id="_hrpt2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hrpt2.Clinical_Description"><h3>Clinical Description</h3><p>The spectrum of <i>CDC73</i>-related disorders includes the following phenotypes:</p><ul><li class="half_rhythm"><div>Hyperparathyroidism-jaw tumor (HPT-JT) syndrome</div></li><li class="half_rhythm"><div>Parathyroid carcinoma</div></li><li class="half_rhythm"><div>Familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism (FIHP)</div></li></ul><p>The following sections describe the clinical characteristics that can be seen across the spectrum.</p><div id="hrpt2.Primary_Hyperparathyroidism"><h4>Primary Hyperparathyroidism</h4><p>Individuals with primary hyperparathyroidism may be asymptomatic or may present with nephrolithiasis, reduced bone mass, fatigue, muscle weakness, bone or joint pain, and/or constipation.</p><p>Primary hyperparathyroidism occurs in up to 95% of individuals with HPT-JT syndrome; the onset is typically in late adolescence or early adulthood. The earliest reported age of hypercalcemia is seven years [<a class="bk_pop" href="#hrpt2.REF.pichardolowden.2011.602">Pichardo-Lowden et al 2011</a>]. The median age of diagnosis of primary hyperparathyroidism reported by <a class="bk_pop" href="#hrpt2.REF.bricaire.2013.e403">Bricaire et al [2013]</a> was 27 years (range 12-58) in individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; the mean age of diagnosis reported by <a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al [2017]</a> was 32 years &#x000b1;15 years. Penetrance increases with age: in a Dutch population the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of primary hyperparathyroidism in HPT-JT syndrome at ages 25, 50, and 70 was reported to be 8%, 53%, and 75%, respectively [<a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>].</p><p>In most individuals with HPT-JT syndrome, hyperparathyroidism is caused by a single benign parathyroid adenoma, which is often cystic or has atypical histologic features. Many families segregating a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have at least one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> member with a cystic, malignant, and/or atypical parathyroid tumor. A second parathyroid tumor may occur synchronously or metachronously months to decades after appearance of the first tumor. In approximately 10%-15% of individuals with HPT-JT syndrome, primary hyperparathyroidism is caused by parathyroid carcinoma. The earliest reported age at diagnosis of parathyroid carcinoma is eight years in a girl with pulmonary metastases [<a class="bk_pop" href="#hrpt2.REF.davidson.2016.32">Davidson et al 2016</a>]. However, onset may be delayed until the sixth decade [<a class="bk_pop" href="#hrpt2.REF.bradley.2006.299">Bradley et al 2006</a>]. Non-functioning parathyroid carcinomas have also been reported [<a class="bk_pop" href="#hrpt2.REF.guarnieri.2006.2827">Guarnieri et al 2006</a>].</p><p><b>Jaw tumors.</b> Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome [<a class="bk_pop" href="#hrpt2.REF.chen.2003.634">Chen et al 2003</a>]. Some ossifying fibromas present as an enlarging visible or palpable mass, whereas others are only detected on dental x-ray. Although benign, these tumors can disrupt normal dentition, impair breathing, and be of significant cosmetic concern. Tumors may occasionally be bilateral/multifocal and may recur. The tumors are considered aggressive and continue to enlarge if not treated.</p><p>The frequency of <i>CDC73</i> pathogenic variants in individuals with ossifying fibromas of the jaw has not been extensively studied. <a class="bk_pop" href="#hrpt2.REF.pimenta.2006.735">Pimenta et al [2006]</a> found a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of three individuals with an apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ossifying fibroma of the mandible, but not in an individual with an apparently sporadic juvenile ossifying fibroma of the mandible. <a class="bk_pop" href="#hrpt2.REF.haag.2008">Haag et al [2008]</a> and <a class="bk_pop" href="#hrpt2.REF.kutcher.2013.e175">Kutcher et al [2013]</a> reported individuals with heterozygous germline <i>CDC73</i> pathogenic variants who had an apparently sporadic ossifying fibroma and later developed primary hyperparathyroidism. <a class="bk_pop" href="#hrpt2.REF.chen.2016.91">Chen et al [2016]</a> reported 19 children and 21 adults with sporadic ossifying fibromas, and no individual had a germline <i>CDC73</i> pathogenic variant identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> (<a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> was not performed); two individuals had somatic <i>CDC73</i> pathogenic variants confined to the ossifying fibroma.</p><p>The specific features of jaw tumors that develop in HPT-JT syndrome have not been well defined; in fact, pathologists disagree on the nomenclature used to classify fibro-osseous lesions. Most jaw tumors in HPT-JT syndrome are reported as ossifying fibromas / cementifying fibromas that occur in molar or premolar areas [<a class="bk_pop" href="#hrpt2.REF.chen.2003.634">Chen et al 2003</a>], most often appear to be radiographically radiolucent, and usually develop prior to the third decade of life. In contrast, <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> tumors tend to appear as mixed radiolucent/radiopaque lesions [<a class="bk_pop" href="#hrpt2.REF.aldred.2006.212">Aldred et al 2006</a>] and typically develop after the third decade of life [<a class="bk_pop" href="#hrpt2.REF.szab_.1995.944">Szab&#x000f3; et al 1995</a>].</p><p>Juvenile fibromas are histologic variants of ossifying fibromas that, when they occur sporadically, tend to occur at a younger mean age than ossifying fibromas. It is not clear whether juvenile fibromas are part of HPT-JT syndrome.</p><p>Of note, the jaw tumors of HPT-JT syndrome are distinct from the "brown" tumors associated with severe hyperparathyroidism (osteitis fibrosa cystica) and do not resolve following curative parathyroidectomy.</p><p><b>Renal manifestations.</b> Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) <a href="/books/n/gene/wilms-ov/">Wilms tumor</a> have also been reported.</p><p>Renal cystic disease is variable and ranges from a few minor cysts to bilateral polycystic disease presenting with end-stage renal disease (ESRD) [<a class="bk_pop" href="#hrpt2.REF.tan.2004.895">Tan &#x00026; Teh 2004</a>]. Cysts have also been observed in association with rare solid tumors, which were histologically similar to mixed epithelial-stromal tumors or adult mesoblastic nephroma (described in one family), or hamartomatous-type tumors [<a class="bk_pop" href="#hrpt2.REF.teh.1996.4204">Teh et al 1996</a>, <a class="bk_pop" href="#hrpt2.REF.tan.2004.895">Tan &#x00026; Teh 2004</a>].</p><p>Malignant progression of these tumors has not yet been reported; however, one individual with HPT-JT syndrome had both papillary renal carcinoma and multiple renal cell adenomas [<a class="bk_pop" href="#hrpt2.REF.haven.2000.1449">Haven et al 2000</a>].</p><p>Wilms tumor has been reported in three unrelated families with HPT-JT syndrome, including an individual who developed bilateral Wilms tumor at age 53 years [<a class="bk_pop" href="#hrpt2.REF.kakinuma.1994.123">Kakinuma et al 1994</a>, <a class="bk_pop" href="#hrpt2.REF.szab_.1995.944">Szab&#x000f3; et al 1995</a>].</p><p><b>Uterine tumors.</b> Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. In one study of HPT-JT kindreds, uterine pathology was described in women who underwent hysterectomy for menorrhagia [<a class="bk_pop" href="#hrpt2.REF.bradley.2005.18">Bradley et al 2005</a>]. The following tumors were identified at time of surgery (average age 35 years; range 23-55 years): adenomyosis (8), adenofibroma (5), endometrial hyperplasia (4), leiomyoma (4), and adenosarcoma (2).</p><p>Multiple adenomyomatous uterine polyps that appeared to have a common embryologic origin (the mesodermal m&#x000fc;llerian duct system) were reported in two sisters with likely HPT-JT syndrome [<a class="bk_pop" href="#hrpt2.REF.fujikawa.1998.557">Fujikawa et al 1998</a>].</p><p>In addition, the observation that women with HPT-JT syndrome have a higher rate of miscarriage than unaffected controls and a lower rate of fertility than both unaffected controls and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males suggests that uterine tumors may contribute to decreased reproductive fitness of women with HPT-JT syndrome.</p><p><b>Other tumors.</b> Pancreatic adenocarcinoma, testicular mixed germ cell tumor, and H&#x000fc;rthle cell thyroid adenoma were reported in individuals in a large kindred with HPT-JT syndrome, as were colon adenocarcinoma, leukemia, papillary thyroid carcinoma, and chronic lymphatic leukemia in other kindreds. Papillary thyroid carcinoma and a neurofibroma were reported in individuals with HPT-JT syndrome [<a class="bk_pop" href="#hrpt2.REF.mallette.1987.54">Mallette et al 1987</a>, <a class="bk_pop" href="#hrpt2.REF.inoue.1995.225">Inoue et al 1995</a>, <a class="bk_pop" href="#hrpt2.REF.haven.2000.1449">Haven et al 2000</a>, <a class="bk_pop" href="#hrpt2.REF.iacobone.2009.817">Iacobone et al 2009</a>]. However, it is not clear that these tumors are present in a higher frequency in individuals with HPT-JT syndrome than in the general population nor that these tumors were caused by a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="hrpt2.Parathyroid_Carcinoma"><h4>Parathyroid Carcinoma</h4><p>Clinical manifestations of parathyroid carcinoma can include palpable neck mass, renal calculi, hoarseness, difficulty speaking or swallowing, muscle weakness, nausea/vomiting, altered mental status, bone pain, and/or pathologic fractures. Parathyroid carcinomas are most often associated with extremely high serum calcium concentration (&#x0003e;12 mg/dL) and extremely high iPTH levels (&#x0003e;3x the upper limit of normal). However, non-functioning parathyroid carcinoma has rarely occurred in individuals with a <i>CDC73-</i>related disorder [<a class="bk_pop" href="#hrpt2.REF.guarnieri.2006.2827">Guarnieri et al 2006</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in 18%-29% of individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> parathyroid carcinoma (i.e., no family history of <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> features or primary hyperparathyroidism) [<a class="bk_pop" href="#hrpt2.REF.carpten.2002.676">Carpten et al 2002</a>, <a class="bk_pop" href="#hrpt2.REF.shattuck.2003.1722">Shattuck et al 2003</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2004.5583">Cetani et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2007.547">Cetani et al 2007</a>, <a class="bk_pop" href="#hrpt2.REF.haven.2007.370">Haven et al 2007</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2013.186">Cetani et al 2013</a>, <a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>].</p></div><div id="hrpt2.Familial_Isolated_Hyperparathyroid"><h4>Familial Isolated Hyperparathyroidism</h4><p>Familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism (FIHP) is characterized by primary hyperparathyroidism without other associated <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> features. Individuals with <i>CDC73-</i>related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified, and individuals in these families may still develop parathyroid carcinoma. The overall prevalence of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> pathogenic variants in families with FIHP has been estimated to be between 7% and 26% [<a class="bk_pop" href="#hrpt2.REF.cetani.2004.5583">Cetani et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.simonds.2004.96">Simonds et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.villablanca.2004.e32">Villablanca et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.warner.2004.155">Warner et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.bradley.2006.299">Bradley et al 2006</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2006.146">Cetani et al 2006</a>, <a class="bk_pop" href="#hrpt2.REF.mizusawa.2006.9">Mizusawa et al 2006</a>, <a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>]. A <i>CDC73</i> pathogenic variant has been identified in approximately 1%-2% of individuals with early-onset (age &#x0003c;45 <i>y</i>ears), apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> primary hyperparathyroidism [<a class="bk_pop" href="#hrpt2.REF.starker.2012.44">Starker et al 2012</a>, <a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>].</p><p>The vast majority of individuals with <i>CDC73-</i>related FIHP have had: (a) at least one family member with a histopathologic diagnosis of parathyroid carcinoma; and/or (2) a parathyroid adenoma with atypical or cystic features [<a class="bk_pop" href="#hrpt2.REF.cetani.2004.5583">Cetani et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.simonds.2004.96">Simonds et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.villablanca.2004.e32">Villablanca et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.mizusawa.2006.9">Mizusawa et al 2006</a>].</p></div></div><div id="hrpt2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Although no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> for <i>CDC73</i> pathogenic variants have been formally established to date, it has been suggested that pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are more likely to be associated with the FIHP phenotype; pathogenic variants that cause gross disruption of the protein product are more likely to be associated with the HPT-JT phenotype. However, some variants (e.g., <a class="figpopup" href="/books/NBK3789/table/hrpt2.T.cdc73_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="fighrpt2Tcdc73pathogenicvariantsdiscus" rid-ob="figobhrpt2Tcdc73pathogenicvariantsdiscus">c.679_680insAG</a>, <a class="figpopup" href="/books/NBK3789/table/hrpt2.T.cdc73_pathogenic_variants_discus/?report=objectonly" target="object" rid-figpopup="fighrpt2Tcdc73pathogenicvariantsdiscus" rid-ob="figobhrpt2Tcdc73pathogenicvariantsdiscus">c.131+1G&#x0003e;A</a>) have been reported in association with more than one <i>CDC73</i>-associated phenotype [<a class="bk_pop" href="#hrpt2.REF.cardoso.2017.1621">Cardoso et al 2017</a>]. In reviewing the reported pathogenic variants and associated phenotypes to date, families with FIHP appear to have a higher ratio of missense to frameshift/<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants than families with HPT-JT syndrome (4/7 vs 3/38, respectively) [<a class="bk_pop" href="#hrpt2.REF.iacobone.2009.817">Iacobone et al 2009</a>, <a class="bk_pop" href="#hrpt2.REF.newey.2010">Newey et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.panicker.2010.513">Panicker et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.rekik.2010.121">Rekik et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.cavaco.2011.44">Cavaco et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.frankraue.2011.477">Frank-Raue et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.pichardolowden.2011.602">Pichardo-Lowden et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.siu.2011.695">Siu et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.starker.2012.44">Starker et al 2012</a>, <a class="bk_pop" href="#hrpt2.REF.kutcher.2013.e175">Kutcher et al 2013</a>].</p></div><div id="hrpt2.Penetrance"><h3>Penetrance</h3><p>While the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in HPT-JT syndrome is estimated at 80%-90%, lower penetrance in females has been reported in two families [<a class="bk_pop" href="#hrpt2.REF.teh.1996.4204">Teh et al 1996</a>] and was closer to 70% in two different studies [<a class="bk_pop" href="#hrpt2.REF.bradley.2005.18">Bradley et al 2005</a>, <a class="bk_pop" href="#hrpt2.REF.iacobone.2009.817">Iacobone et al 2009</a>]. The overall age-related penetrance in a Dutch population was estimated to be 11% at age 25, 65% at age 50, and 83% at age 70 [<a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>].</p></div><div id="hrpt2.Nomenclature"><h3>Nomenclature</h3><p>Hyperparathyroidism-jaw tumor (HPT-JT) syndrome is also known as <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> primary hyperparathyroidism with multiple ossifying jaw fibromas and familial cystic parathyroid adenomatosis.</p></div><div id="hrpt2.Prevalence"><h3>Prevalence</h3><p>The prevalence of HPT-JT syndrome is not well established.</p></div></div><div id="hrpt2.Genetically_Related_Allelic_Disord"><h2 id="_hrpt2_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>CDC73</i>.</p></div><div id="hrpt2.Differential_Diagnosis"><h2 id="_hrpt2_Differential_Diagnosis_">Differential Diagnosis</h2><p>The following disorders should be considered in the differential diagnosis of <i>CDC73-</i>related disorders<i>.</i></p><div id="hrpt2.Primary_Hyperparathyroidism__Famil"><h3>Primary Hyperparathyroidism / Familial Isolated Hyperparathyroidism</h3><p><b>Sporadic</b>
<b>primary hyperparathyroidism.</b> Primary hyperparathyroidism has a prevalence of one to three per 1,000 in the general population with a female-to-male ratio of approximately 3:1. Sporadic primary hyperparathyroidism is typically caused by a single parathyroid adenoma with a peak age at onset in the sixth decade of life.</p><p><a href="/books/n/gene/men1/"><b>Multiple endocrine neoplasia type 1</b></a>
<b>(MEN1)</b> is the most common known hereditary cause of primary hyperparathyroidism, accounting for 2%-4% of primary hyperparathyroidism. MEN1-associated primary hyperparathyroidism is characterized by onset in late adolescence to early adulthood (with nearly all individuals <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by age 50 years), multiglandular disease, and histology usually demonstrating parathyroid hyperplasia. Classic MEN1 is also associated with pituitary adenomas and gastroenteropancreatic neuroendocrine tumors, primarily gastrinomas and insulinomas. <i>MEN1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants have also been reported in approximately 20% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> primary hyperparathyroidism [<a class="bk_pop" href="#hrpt2.REF.warner.2004.155">Warner et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2006.146">Cetani et al 2006</a>, <a class="bk_pop" href="#hrpt2.REF.mizusawa.2006.9">Mizusawa et al 2006</a>]. MEN1 is caused by pathogenic variants in <i>MEN1</i>; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b>Multiple endocrine neoplasia type 4</b> (<b>MEN4</b>; OMIM <a href="http://omim.org/entry/610755" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610755</a>) is a recently described hereditary endocrine neoplasia syndrome caused by <i>CDKN1B</i> pathogenic variants. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of MEN4 overlaps with that of MEN1; however, less is known about its <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> and associated lifetime risk for endocrine tumors. Primary hyperparathyroidism tends to occur at a later age in MEN4 than in MEN1. The proportion of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> or <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> primary hyperparathyroidism explained by MEN4 remains unknown. Additional endocrine tumors seen in individuals with MEN4 include pituitary adenomas and pancreatic neuroendocrine tumors, which also appear to exhibit a less aggressive course than those seen in MEN1. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b>Familial hypocalciuric hypercalcemia (FHH)</b></p><ul><li class="half_rhythm"><div>Familial hypocalciuric hypercalcemia type 1 (benign <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypercalcemia) (OMIM <a href="http://omim.org/entry/145980" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">145980</a>) is a benign condition characterized by hypercalcemia, low urinary calcium excretion (assessed via a calcium/creatinine clearance ratio), normal to minimally elevated PTH levels, and frequent hypermagnesemia. Biochemical findings in FHH can overlap with those of primary hyperparathyroidism. However, FHH is not a pathologic process and represents a higher, yet normal, set point for serum calcium concentrations. FHH is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>CASR</i>.</div></li><li class="half_rhythm"><div>Heterozygous <i>CASR</i> pathogenic variants have also been reported in 14%-18% of individuals with FIHP [<a class="bk_pop" href="#hrpt2.REF.simonds.2002.1">Simonds et al 2002</a>, <a class="bk_pop" href="#hrpt2.REF.warner.2004.155">Warner et al 2004</a>].</div></li><li class="half_rhythm"><div>Homozygous <i>CASR</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants are associated with neonatal severe primary hyperparathyroidism (NSHPT) (OMIM <a href="http://omim.org/entry/239200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">239200</a>).</div></li><li class="half_rhythm"><div>In a smaller proportion of individuals with FHH, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>GNA11</i> and <i>AP2S1</i> &#x02013; which cause FHH types 2 and 3, respectively (OMIM <a href="http://omim.org/entry/145981" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">145981</a>, <a href="http://omim.org/entry/600740" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600740</a>) &#x02013; have been identified. It is not known whether pathogenic variants in these genes account for any proportion of FIHP.</div></li></ul><p><b>Familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> hyperparathyroidism type 4</b> (OMIM <a href="http://omim.org/entry/617343" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617343</a>). Recently, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> activating pathogenic variants in <i>GCM2</i> have been found in multiple kindreds with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> isolated primary hyperparathyroidism, and early data suggest that individuals with <i>GCM2-</i>associated primary hyperparathyroidism are more likely to have aggressive disease, including a lesser rate of biochemical cure and an increased incidence of parathyroid carcinoma. Individuals in these kindreds do not appear to be at increased risk for other endocrine tumors. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b>Multiple endocrine neoplasia type 2A (MEN2A).</b> Although primary hyperparathyroidism occurs in up to 20%-30% of individuals with MEN2A, it is rarely the presenting feature. MEN2A is generally not suspected unless the more common manifestations of MEN2A (including medullary thyroid carcinoma and pheochromocytoma) are present. MEN2A is caused by pathogenic variants in <i>RET</i>; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. See <a href="/books/n/gene/men2/">Multiple Endocrine Neoplasia Type 2</a>.</p><p><b>An as-yet unknown <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</b> In many individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> primary hyperparathyroidism, an underlying genetic cause cannot be identified. A susceptibility <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> has been mapped to 2p13.3-p14 [<a class="bk_pop" href="#hrpt2.REF.warner.2006.e12">Warner et al 2006</a>], and inheritance of familial <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> primary hyperparathyroidism is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p></div><div id="hrpt2.Jaw_Tumors"><h3>Jaw Tumors</h3><p>The differential diagnosis for ossifying fibromas of the jaw seen as part of HPT-JT syndrome is dependent on the radiologic characteristics of the lesions, specifically whether they are radiolucent, have mixed radiographic features, or are completely radiopaque [<a class="bk_pop" href="#hrpt2.REF.chang.2008.288">Chang et al 2008</a>]. One of the most important diagnoses to consider is fibrous dysplasia, which is a reactive lesion rather than a true neoplasm. In addition, osseous dysplasia, including focal osseous dysplasia, should be considered [<a class="bk_pop" href="#hrpt2.REF.de_andrade.2013.662">de Andrade et al 2013</a>]. Benign lesions that can be confused with HPT-JT on panoramic x-rays include but are not limited to periapical cementoplasia, giant cell reparative granuloma, and <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> bone cyst. Benign anatomic variations such as exostosis, mandibular tori, maxillary torus palatinus, and the lingual concavity of the body of the mandible can also be misinterpreted as jaw tumors. See <a class="bk_pop" href="#hrpt2.REF.chang.2008.288">Chang et al [2008]</a> and <a class="bk_pop" href="#hrpt2.REF.de_andrade.2013.662">de Andrade et al [2013]</a> for clinicopathologic case series of patients with ossifying fibromas of the jaw, including discussion and review of pertinent differential diagnoses to consider.</p></div><div id="hrpt2.Renal_Cysts"><h3>Renal Cysts</h3><div id="hrpt2.Sporadic_Renal_Cysts"><h4>Sporadic Renal Cysts</h4><p>The prevalence of at least one renal cyst detected by ultrasound examination in the general population [<a class="bk_pop" href="#hrpt2.REF.ravine.1993.803">Ravine et al 1993</a>]:</p><ul><li class="half_rhythm"><div>0% before age 29 years</div></li><li class="half_rhythm"><div>~1.7% between ages 30 and 49 years</div></li><li class="half_rhythm"><div>11.5% between ages 50 and 70 years</div></li><li class="half_rhythm"><div>22% after age 70 years</div></li></ul><p>The prevalence of bilateral renal cysts (at least one cyst in each kidney):</p><ul><li class="half_rhythm"><div>1% between ages 30 and 49 years</div></li><li class="half_rhythm"><div>4% between ages 50 and 69 years</div></li><li class="half_rhythm"><div>9% after age 70 years</div></li></ul></div><div id="hrpt2.Syndromic_Renal_Cysts"><h4>Syndromic Renal Cysts</h4><p><a href="/books/n/gene/pkd-ad/"><b>Autosomal dominant polycystic kidney disease</b></a>
<b>(ADPKD)</b> is characterized by the development of multiple bilateral renal cysts, cysts in other organs (primarily the liver, seminal vesicles, pancreas, and arachnoid membrane), vascular abnormalities, and abdominal wall hernias, with onset typically in adulthood. In approximately 85% of individuals with ADPKD, pathogenic variants in <i>PKD1</i> are causative; in approximately 15%, pathogenic variants in <i>PKD2</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b>Other <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> conditions</b> associated with renal cystic disease are usually diagnosed by the presence of additional manifestations:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/tuberous-sclerosis/"><b>Tuberous sclerosis complex</b></a> is also associated with abnormalities of the skin (hypomelanotic macules, facial angiofibromas, shagreen patches, fibrous facial plaques, ungual fibromas), brain (cortical tubers, subependymal nodules, seizures, intellectual disability / developmental delay), and heart (rhabdomyomas, arrhythmias). Among those in whom a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be identified, pathogenic variants in <i>TSC1</i> are found in 31% and pathogenic variants in <i>TSC2</i> in 69%; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/vhl/"><b>von Hippel-Lindau syndrome</b></a>
<b>(VHL)</b> is associated with retinal and/or central nervous system hemangioblastomas, clear cell renal carcinoma, pheochromocytoma, cysts and neuroendocrine tumors of the pancreas, and cystadenomas of the epididymis in males and broad ligament in females. VHL is caused by pathogenic variants in <i>VHL</i>; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li></ul></div></div></div><div id="hrpt2.Management"><h2 id="_hrpt2_Management_">Management</h2><div id="hrpt2.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual identified to have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CDC73</i>, the following are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Evaluation for primary hyperparathyroidism. Measurement of concomitant iPTH levels and serum calcium concentration; measurement of 25-(OH) vitamin D to rule out vitamin D deficiency as a confounder.</div></li><li class="half_rhythm"><div>Baseline bone density of the lumbar spine, hips, and distal radius by dual-energy x-ray absorptiometry (DXA) and 24-hour urine collection for calcium in individuals with evidence of primary hyperparathyroidism</div></li><li class="half_rhythm"><div>Evaluation for jaw tumors. Panoramic jaw x-ray with neck shielding</div></li><li class="half_rhythm"><div>Evaluation for renal lesions. Renal ultrasound examination preferred; CT and/or MRI as clinically indicated</div></li><li class="half_rhythm"><div>Evaluation for uterine tumors in women starting at reproductive age. Pelvic examination as part of routine gynecologic care; pelvic ultrasound examination (preferred) and other imaging studies (CT and/or MRI) as clinically indicated</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hrpt2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Primary hyperparathyroidism.</b> While the preferred treatment for <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> primary hyperparathyroidism is parathyroidectomy by a high-volume parathyroid surgeon (most of whom prefer a minimally invasive or targeted approach), the optimal surgical approach to primary hyperparathyroidism in HPT-JT syndrome has not yet been established. However, because many individuals with HPT-JT syndrome present with a single, benign parathyroid tumor, a minimally invasive approach to remove the parathyroid tumor followed by close monitoring for recurrent primary hyperparathyroidism has been suggested. Minimally invasive parathyroidectomy requires the use of:</p><ul><li class="half_rhythm"><div class="half_rhythm">Preoperative imaging (e.g., ultrasound examination, <sup>99m</sup>Tc-sestamibi scanning [often with concomitant SPECT/CT] or 4-dimensional CT to localize the abnormal parathyroid gland);</div><div class="half_rhythm">AND</div></li><li class="half_rhythm"><div class="half_rhythm">Intraoperative measurement of iPTH (IOPTH) to ensure an adequate resection of all hyperfunctioning tissue.</div></li></ul><p>IOPTH involves measurement of serum iPTH at the initiation of the surgery and again at five minutes and at ten minutes following excision of the presumed parathyroid tumor. An IOPTH that drops more than 50% in the first five minutes is highly suggestive of cure. The success rate of such a measurement is greater than 95%. If the IOPTH does not drop more than 50% in five minutes, residual hyperfunctioning tissue likely remains in situ and further exploration is recommended to look for other abnormally hyperfunctioning glands. Standard cervical exploration to visualize all four parathyroid glands is generally not recommended unless it appears that residual hyperfunctioning tissue remains.</p><p>If there is any suggestion of adherence of the parathyroid gland to the thyroid parenchyma, a concomitant thyroid lobectomy should be considered. In the past, prophylactic total parathyroidectomy was suggested to reduce the risk of parathyroid carcinoma in HPT-JT syndrome; however, given the difficulty in treating postsurgical hypoparathyroidism, this approach is not widely accepted.</p><p>In 2009 Iacobone et al evaluated 17 individuals with HPT-JT syndrome from three large families; 82% of individuals had single gland disease. These findings supported unilateral operation when preoperative imaging targeted the offending gland. Because the disease usually involves a single gland, a multigland resection increases the risk for hypoparathyroidism with no true benefit of reducing disease recurrence. Therefore, subtotal parathyroidectomy (the standard surgery in <a href="/books/n/gene/men1/">MEN1</a>) is not recommended.</p><p><a class="bk_pop" href="#hrpt2.REF.mehta.2014.1315">Mehta et al [2014]</a> found that in their cohort of 16 individuals from seven families, 31% of individuals had multiglandular disease and 37.5% of individuals developed parathyroid carcinoma. These data were collected for individuals over three decades with variable preoperative imaging. This group recommended bilateral neck exploration to assess all four parathyroid glands and <i>en bloc</i> resection of parathyroid tumors in individuals with HPT-JT syndrome given the increased risk of multiglandular disease and malignancy.</p><p>Regardless of the surgical approach, the risk of recurrent and/or new metachronous disease exists; therefore, regular lifelong serum testing for biochemical evidence of hyperparathyroidism is recommended (see <a href="#hrpt2.Surveillance">Surveillance</a>).</p><p>Parathyroid carcinoma is suspected in those with extremely elevated serum calcium and iPTH levels, more profound symptoms, palpable cervical disease, and clear radiographic evidence of parathyroid neoplasia. In this situation, an <i>en bloc</i> resection including the ipsilateral thyroid lobe is indicated. Care to prevent fracture of the tumor, which could seed the local area and cause parathyromatosis, is critical. Experienced surgeons can usually distinguish typical benign parathyroid tissue from carcinoma. Benign tissue is peanut butter colored, soft, small, and non-adherent to surrounding structures. Benign tumors are usually oval, round, or kidney-shaped in appearance. In contrast, parathyroid carcinoma is usually hard, firm, white-gray, large, and intimately attached to surrounding structures [Author, personal experience].</p><p>For severe or symptomatic hypercalcemia, individuals can be treated with an infusion of zoledronic acid or pamidronate for acute management. For long-term control of hypercalcemia that occurs in individuals who are unable to undergo parathyroidectomy and for the treatment of parathyroid carcinoma-related hypercalcemia, cinacalcet hydrochloride (Sensipar<sup>&#x000ae;</sup>), a calcimimetic that binds to the calcium-sensing receptor, can be used for medical management [<a class="bk_pop" href="#hrpt2.REF.messa.2011.517">Messa et al 2011</a>]. Cinacalcet has proven effective in individuals with inoperable parathyroid carcinoma [<a class="bk_pop" href="#hrpt2.REF.silverberg.2007.3803">Silverberg et al 2007</a>] and has been used in an individual with <i>CDC73</i>-associated primary hyperparathyroidism for whom parathyroidectomy was considered high risk [<a class="bk_pop" href="#hrpt2.REF.sato.2016.91">Sato et al 2016</a>].</p><p><b>Jaw tumors.</b> Jaw tumors should be treated surgically as indicated based on the size, location, and symptoms of the lesion. Treatment of choice is complete resection, which may not be possible in all individuals. There are no well-defined medical approaches to unresectable jaw tumors. Individuals with a history of jaw tumors should be followed closely because of the possibility of recurrence.</p><p><b>Renal manifestations.</b> No treatment guidelines for renal manifestations associated with HPT-JT syndrome have been proposed to date. Management guidelines are available for other polycystic kidney diseases, such as <a href="/books/n/gene/pkd-ad/">autosomal dominant polycystic kidney disease</a>; however, the natural history and likelihood of ESRD is likely to be different in HPT-JT syndrome-associated renal disease. Individuals with evidence of cystic kidney disease should be managed by nephrologists on a case-by-case basis.</p><p><b>Uterine tumors.</b> No treatment guidelines for uterine manifestations associated with HPT-JT syndrome have been proposed to date. Individuals with evidence of a uterine tumor should be managed by a gynecologist on a case-by-case basis.</p></div><div id="hrpt2.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p>Prophylactic total parathyroidectomy has been suggested to reduce the risk of parathyroid carcinoma. However, given the rarity of parathyroid carcinoma in individuals with HPT-JT syndrome and the difficulty in treating postsurgical hypoparathyroidism, this approach is not recommended.</p></div><div id="hrpt2.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>The risk of postoperative hypoparathyroidism can be minimized by: ensuring normal preoperative 25-(OH) vitamin D concentrations; recognizing risk factors for hungry bone syndrome preoperatively (e.g., elevated serum alkaline phosphatase concentration); and implementing close postoperative monitoring that includes prompt replacement of calcium and vitamin D as indicated. Minimization of postoperative nausea and vomiting can help prevent an increase in venous pressure, which could lead to oozing and devascularization of the remaining in situ parathyroid glands.</p><p>Biopsy of extrathyroidal tissue in the neck should be avoided when possible to reduce the risk of seeding of a possible parathyroid carcinoma.</p><p>An <i>en bloc</i> resection should be considered in all individuals suspected of having parathyroid carcinoma in order to optimize a surgical cure and prevent positive surgical margins or seeding of parathyroid tissue (parathyromatosis) during removal.</p></div><div id="hrpt2.Surveillance"><h3>Surveillance</h3><p>There are currently no well-established surveillance guidelines for individuals with a <i>CDC73-</i>related disorder. Based on an extensive literature review, the following are recommended:</p><ul><li class="half_rhythm"><div>Annual serum calcium, iPTH, and 25-(OH) vitamin D (to evaluate for possible coexisting vitamin D deficiency as a cause of elevated iPTH levels or unexpectedly "normal" calcium concentrations) starting at age five years.</div></li><li class="half_rhythm"><div>Individuals with a history of parathyroid carcinoma, who develop a rise in calcium levels, should be evaluated for a new primary parathyroid tumor or recurrence/progression of malignant disease.</div></li><li class="half_rhythm"><div>Consider periodic parathyroid ultrasound examination for the detection of non-functioning parathyroid carcinoma.</div></li><li class="half_rhythm"><div>Obtain panoramic x-ray dental imaging with neck shielding at least every five years, in addition to regular dental hygiene maintenance, starting at age ten years. Dental providers should be notified of the presence of a <i>CDC73</i>-related disorder and the need for monitoring for osseous fibromas of the maxilla and mandible.</div></li><li class="half_rhythm"><div>Monitor for kidney lesions by renal ultrasound examination at least every five years starting at the age of diagnosis. Serum creatinine concentrations should be monitored in those individuals with renal cysts. Individuals with solid lesions should be referred for appropriate subspecialty care.</div></li><li class="half_rhythm"><div>Starting at reproductive age, women with a <i>CDC73</i>-related disorder should undergo regular gynecologic care (including pelvic examination). Care providers in obstetrics and gynecology should be notified of the risk of uterine tumors. Pelvic ultrasound examination should be obtained in any woman with a menstrual disorder (particularly abnormal uterine bleeding or menorrhagia) with further imaging studies (CT or MRI) as clinically indicated.</div></li></ul></div><div id="hrpt2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Dehydration</div></li><li class="half_rhythm"><div>Radiation exposure</div></li><li class="half_rhythm"><div>Biopsy of extrathyroidal tissue in the neck, which increases the risk of seeding of parathyroid tissue</div></li></ul></div><div id="hrpt2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Molecular genetic testing for the <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> should be offered to at-risk relatives beginning at age five years in order to identify as early as possible those who would benefit from initiation of surveillance, treatment, and/or preventive measures.</p><p>See <a href="#hrpt2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hrpt2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Primary hyperparathyroidism during pregnancy may pose increased risks to the mother (symptomatic hypercalcemia) and to the fetus (intrauterine growth retardation, preterm delivery, intrauterine fetal demise, and/or postpartum neonatal hypocalcemia). Conservative observation may be appropriate for mild asymptomatic hypercalcemia, but for symptomatic primary hyperparathyroidism or evidence of adverse effects on the fetus, surgery (preferred in the second trimester) is required for definitive treatment. These women should be managed in conjunction with a maternal-fetal medicine specialist.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for more information on medication use during pregnancy.</p></div><div id="hrpt2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="hrpt2.Genetic_Counseling"><h2 id="_hrpt2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hrpt2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>CDC73</i>-related disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hrpt2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Some individuals with a <i>CDC73</i>-related disorder inherited a <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>Alternatively, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual may have the disorder as the result of a <i>de</i>
<i>novo</i>
<i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., neither parent is known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with a <i>CDC73</i>-related disorder).</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. In one reported case, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual had an affected parent with somatic and germline mosaicism [<a class="bk_pop" href="#hrpt2.REF.villablanca.2004.e32">Villablanca et al 2004</a>].</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with a <i>CDC73</i>-related disorder may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> [<a class="bk_pop" href="#hrpt2.REF.villablanca.2004.e32">Villablanca et al 2004</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%. Age of onset, severity, type of symptoms, or rate of progression cannot be predicted in sibs who inherit a <i>CDC73</i> pathogenic variant.</div></li><li class="half_rhythm"><div>If the parents have been tested for the <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and the pathogenic variant was not detected in either parent's leukocyte DNA, the risk to sibs is slightly greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>The absence of clinical symptoms in parents whose genetic status is unknown cannot be used to predict risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with a <i>CDC73</i>-related disorder has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="hrpt2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hrpt2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hrpt2.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hrpt2.Resources"><h2 id="_hrpt2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/007264.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parathyroid Cancer</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/types/parathyroid" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parathyroid Cancer</a></div></li><li class="half_rhythm"><div><b>National Kidney and Urologic Diseases Information Clearinghouse (NKUKIC)</b></div><div><b>Phone:</b> 800-860-8747 (toll-free); 866-569-1162 (toll-free TTY)Y)</div><div><b>Email:</b> healthinfo@niddk.nih.gov</div><div><a href="https://www.niddk.nih.gov/health-information/endocrine-diseases/primary-hyperparathyroidism" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary hyperparathyroidism</a></div></li></ul></div><div id="hrpt2.Molecular_Genetics"><h2 id="_hrpt2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hrpt2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>CDC73-Related Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3789/table/hrpt2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hrpt2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hrpt2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hrpt2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hrpt2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hrpt2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hrpt2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hrpt2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hrpt2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/79577" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CDC73</i></a></td><td headers="hd_b_hrpt2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=79577" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q31<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hrpt2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q6P1J9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parafibromin</a></td><td headers="hd_b_hrpt2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CDC73" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CDC73 database</a></td><td headers="hd_b_hrpt2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CDC73" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CDC73</a></td><td headers="hd_b_hrpt2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CDC73[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CDC73</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hrpt2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hrpt2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for CDC73-Related Disorders (<a href="/omim/145000,145001,607393,608266" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3789/table/hrpt2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hrpt2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/145000" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">145000</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPERPARATHYROIDISM 1; HRPT1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/145001" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">145001</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPERPARATHYROIDISM 2 WITH JAW TUMORS; HRPT2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607393" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607393</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CELL DIVISION CYCLE 73; CDC73</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608266" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608266</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARATHYROID CARCINOMA</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CDC73</i> (formerly known as <i>HRPT2</i>) spans 1.3 Mb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA and encodes a 2.7-kb transcript from 17 coding exons [<a class="bk_pop" href="#hrpt2.REF.carpten.2002.676">Carpten et al 2002</a>, <a class="bk_pop" href="#hrpt2.REF.bradley.2005.18">Bradley et al 2005</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK3789/#hrpt2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> There are known benign variants in <i>CDC73</i> [<a class="bk_pop" href="#hrpt2.REF.bradley.2006.299">Bradley et al 2006</a>] as well as variants of undetermined clinical significance.</p><p><b>Pathogenic variants.</b> More than 45 pathogenic sequence variants have been described for <i>CDC73</i>. Nonsense, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants as well as small deletions and insertions have been reported in individuals/pedigrees <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with hyperparathyroidism-jaw tumor (HPT-JT) syndrome [<a class="bk_pop" href="#hrpt2.REF.iacobone.2009.817">Iacobone et al 2009</a>, <a class="bk_pop" href="#hrpt2.REF.newey.2010">Newey et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.panicker.2010.513">Panicker et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.rekik.2010.121">Rekik et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.wang.2010.1694">Wang et al 2010</a>, <a class="bk_pop" href="#hrpt2.REF.cavaco.2011.44">Cavaco et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.frankraue.2011.477">Frank-Raue et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.pichardolowden.2011.602">Pichardo-Lowden et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.siu.2011.695">Siu et al 2011</a>, <a class="bk_pop" href="#hrpt2.REF.starker.2012.44">Starker et al 2012</a>, <a class="bk_pop" href="#hrpt2.REF.kutcher.2013.e175">Kutcher et al 2013</a>, <a class="bk_pop" href="#hrpt2.REF.van_der_tuin.2017.4534">van der Tuin et al 2017</a>].</p><p>Most pathogenic variants appear to be unique to individual families; however, some pathogenic variants have been found repeatedly in unrelated families [<a class="bk_pop" href="#hrpt2.REF.cavaco.2004.1747">Cavaco et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.bradley.2005.18">Bradley et al 2005</a>]. The c.766_767delGT variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 appears to be a founder <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Roma families from Portugal [<a class="bk_pop" href="#hrpt2.REF.cavaco.2004.1747">Cavaco et al 2004</a>].</p><p>The importance of <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is highlighted in the study reported by <a class="bk_pop" href="#hrpt2.REF.bricaire.2013.e403">Bricaire et al [2013]</a>, where seven of 20 probands were found to have whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions. Furthermore, among 97 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in whom <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> failed to identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, 7% (7/97) had deletion of one or more exons of <i>CDC73</i> that were detected by deletion/duplication analysis. For other reports of gross deletions see <a class="bk_pop" href="#hrpt2.REF.caron.2011.694">Caron et al [2011]</a>, <a class="bk_pop" href="#hrpt2.REF.casc_n.2011.922">Casc&#x000f3;n et al [2011]</a>, and <a class="bk_pop" href="#hrpt2.REF.domingues.2012.33">Domingues et al [2012]</a>. See also <a href="/books/NBK3789/#hrpt2.molgen.TA">Table A</a>, <b>HGMD</b>.</p><div id="hrpt2.T.cdc73_pathogenic_variants_discus" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>CDC73</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK3789/table/hrpt2.T.cdc73_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hrpt2.T.cdc73_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.131+1G&#x0003e;A</td><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_024529.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_024529<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_078805.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_078805<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.679_680insAG</td><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg227LysfsTer31</td></tr><tr><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.766_767delGT<br />(255/256delTG)</td><td headers="hd_h_hrpt2.T.cdc73_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val256LysfsTer10</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hrpt2.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The 531-amino-acid protein product is called parafibromin. Parafibromin is a subunit of the PAF1 protein complex and likely functions as a <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> [<a class="bk_pop" href="#hrpt2.REF.rozenblattrosen.2005.612">Rozenblatt-Rosen et al 2005</a>]. Three putative nuclear localization signals are thought to be located between codons 76 and 92, codons 192 and 194, and codons 393 and 409 [<a class="bk_pop" href="#hrpt2.REF.bradley.2005.18">Bradley et al 2005</a>, <a class="bk_pop" href="#hrpt2.REF.hahn.2007.5070">Hahn &#x00026; Marsh 2007</a>]. Exon 7 contains a dinucleotide repeat of (AG)5, and several frameshift variants altering this motif have been reported. The finding of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> of the wild type <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in parathyroid tumors from individuals with HPT-JT syndrome strongly supports a tumor suppressor role for <i>CDC73</i> [<a class="bk_pop" href="#hrpt2.REF.bradley.2006.299">Bradley et al 2006</a>]. Parafibromin has also been shown to inhibit cell proliferation by repression of the c-myc proto-oncogene and mediate cyclin D1 repression through histone <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>, further supporting the role of <i>CDC73</i> as a tumor suppressor [<a class="bk_pop" href="#hrpt2.REF.woodard.2005.1272">Woodard et al 2005</a>, <a class="bk_pop" href="#hrpt2.REF.lin.2008.17420">Lin et al 2008</a>, <a class="bk_pop" href="#hrpt2.REF.yang.2010.382">Yang et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The pathogenicity of <i>CDC73</i> whole-gene deletions indicates that inactivation of one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> of parafibromin is the cause of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. This is consistent with the many reported <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>CDC73</i> small deletions/insertions or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> pathogenic variants.</p><div id="hrpt2.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>Sporadic tumors (including parathyroid carcinoma, benign parathyroid tumors, and renal tumors) occurring as single tumors in the absence of any other findings of <i>CDC73</i>-related disorders frequently may harbor somatic variants in <i>CDC73</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable.</p><p><b>Parathyroid carcinoma.</b> Somatic <i>CDC73</i> pathogenic variants are associated with parathyroid carcinoma, but also occur uncommonly in <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> benign parathyroid tumors [<a class="bk_pop" href="#hrpt2.REF.howell.2003.657">Howell et al 2003</a>, <a class="bk_pop" href="#hrpt2.REF.shattuck.2003.1722">Shattuck et al 2003</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2004.5583">Cetani et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.krebs.2005.5015">Krebs et al 2005</a>]. Therefore, somatic variants of <i>CDC73</i> have been implicated in malignant transformation of parathyroid tumors.</p><p>It has been suggested that presence of <i>CDC73</i> somatic pathogenic variants and loss of parafibromin immunostaining could be used as markers of malignant potential in parathyroid neoplasms and as a guide to target genetic screening for HPT-JT syndrome [<a class="bk_pop" href="#hrpt2.REF.tan.2004.6629">Tan et al 2004</a>, <a class="bk_pop" href="#hrpt2.REF.gill.2006.1140">Gill et al 2006</a>, <a class="bk_pop" href="#hrpt2.REF.cetani.2007.547">Cetani et al 2007</a>, <a class="bk_pop" href="#hrpt2.REF.juhlin.2007.501">Juhlin et al 2007</a>, <a class="bk_pop" href="#hrpt2.REF.kruijff.2014.426">Kruijff et al 2014</a>].</p><p><b>Renal tumors.</b> Loss of heterozygosity of the wild type <i>CDC73</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has also been observed in <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> human renal tumors, including clear cell, papillary, and chromophobe renal cell carcinomas, as well as oncocytomas and Wilms tumors [<a class="bk_pop" href="#hrpt2.REF.zhao.2007.3440">Zhao et al 2007</a>].</p><p><b>Ossifying fibroma of the jaw.</b> Heterozygous somatic <i>CDC73</i> pathogenic variants were identified in two of 40 tumors studied from individuals with a <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ossifying jaw fibroma [<a class="bk_pop" href="#hrpt2.REF.chen.2016.91">Chen et al 2016</a>].</p></div></div><div id="hrpt2.References"><h2 id="_hrpt2_References_">References</h2><div id="hrpt2.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 4-9-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF2">National Cancer Institute Statement: Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute). Available <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 4-9-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF3">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="https://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 4-9-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.hampel.2015.70">Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, et al.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. <span><span class="ref-journal">Genet Med. </span>2015;<span class="ref-vol">17</span>:70–87.</span> [<a href="/pubmed/25394175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25394175</span></a>]</div></li></ul></div><div id="hrpt2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.aldred.2006.212">Aldred MJ, Talacko AA, Savarirayan R, Murdolo V, Mills AE, Radden BG, Alimov A, Villablanca A, Larsson C. Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene pathogenic variant. <span><span class="ref-journal">Oral Surg Oral Med Oral Pathol Oral Radiol Endod. </span>2006;<span class="ref-vol">101</span>:212–8.</span> [<a href="/pubmed/16448924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16448924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.bradley.2006.299">Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A, Thakker RV. Parafibromin pathogenic variants in hereditary hyperparathyroidism syndromes and parathyroid tumours. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2006;<span class="ref-vol">64</span>:299–306.</span> [<a href="/pubmed/16487440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16487440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.bradley.2005.18">Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE, Laidler P, Manek S, Robbins CM, Salti IS, Thompson NW, Jackson CE, Thakker RV. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. <span><span class="ref-journal">J Intern Med. </span>2005;<span class="ref-vol">257</span>:18–26.</span> [<a href="/pubmed/15606373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15606373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.bricaire.2013.e403">Bricaire L, Odou MF, Cardot-Bauters C, Delemer B, North MO, Salenave S, Vezzosi D, Kuhn JM, Murat A, Caron P, Sadoul JL, Silve C, Chanson P, Barlier A, Clauser E, Porchet N, Groussin L, Group GTE. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;2013;<span class="ref-vol">98</span>:E403–8.</span> [<a href="/pubmed/23293331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23293331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cardoso.2017.1621">Cardoso L, Stevenson M, Thakker RV. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. <span><span class="ref-journal">Hum Mutat. </span>2017;<span class="ref-vol">38</span>:1621–48.</span> [<a href="/pmc/articles/PMC5698716/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5698716</span></a>] [<a href="/pubmed/28881068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28881068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.caron.2011.694">Caron P, Simonds WF, Maiza JC, Rubin M, Cantor T, Rousseau L, Bilezikian JP, Souberbielle JC, D'Amour P. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2011;<span class="ref-vol">74</span>:694–8.</span> [<a href="/pmc/articles/PMC3089698/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3089698</span></a>] [<a href="/pubmed/21521290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21521290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.carpten.2002.676">Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, H&#x000f6;&#x000f6;g A, Heath H 3rd, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">Nat Genet. </span>2002;<span class="ref-vol">32</span>:676–80.</span> [<a href="/pubmed/12434154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12434154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.casc_n.2011.922">Casc&#x000f3;n A, Huarte-Mendicoa CV, Javier Leandro-Garc&#x000ed;a L, Let&#x000f3;n R, Suela J, Santana A, Costa MB, Comino-M&#x000e9;ndez I, Landa I, S&#x000e1;nchez L, Rodr&#x000ed;guez-Antona C, Cigudosa JC, Robledo M. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2011;<span class="ref-vol">50</span>:922–9.</span> [<a href="/pubmed/21837707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21837707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cavaco.2004.1747">Cavaco BM, Guerra L, Bradley KJ, Carvalho D, Harding B, Oliveira A, Santos MA, Sobrinho LG, Thakker RV, Leite V. Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder pathogenic variant of the HRPT2 gene. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:1747–52.</span> [<a href="/pubmed/15070940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15070940</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cavaco.2011.44">Cavaco BM, Santos R, Felix A, Cavalho D, Lopes JM, Domingues R, Sirgado M, Rei N, Fonseca F, Sangos JR, Sobrinho L, Leite V. Identification of de novo germline pathogenic variants in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. <span><span class="ref-journal">Endocr Pathol. </span>2011;<span class="ref-vol">22</span>:44–52.</span> [<a href="/pubmed/21360064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21360064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cetani.2007.547">Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? <span><span class="ref-journal">Eur J Endocrinol. </span>2007;<span class="ref-vol">156</span>:547–54.</span> [<a href="/pubmed/17468190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17468190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cetani.2013.186">Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, Torregrossa L, Basolo F, Pelizzo MR, Rugge M, Pennelli G, Gasparri G, Papotti M, Volante M, Vignali E, Saponaro F, Marcocci C. CDC73 pathogenic variantal status and loss of parafibromin in the outcome of parathyroid cancer. <span><span class="ref-journal">Endocr Connect. </span>2013;<span class="ref-vol">2</span>:186–95.</span> [<a href="/pmc/articles/PMC3847926/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3847926</span></a>] [<a href="/pubmed/24145611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24145611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cetani.2006.146">Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L, Vignali E, Viacava P, Berti P, Mariotti S, Pinchera A, Marcocci C. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2006;<span class="ref-vol">64</span>:146–52.</span> [<a href="/pubmed/16430712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16430712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.cetani.2004.5583">Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic pathogenic variants in familial and sporadic parathyroid tumors. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:5583–91.</span> [<a href="/pubmed/15531515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15531515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.chang.2008.288">Chang CC, Hung HY, Chang JY, Yu CH, Wang YP, Liu BY, Chiang CP. Central ossifying fibroma: a clinicopathologic study of 28 cases. <span><span class="ref-journal">J Formos Med Assoc. </span>2008;<span class="ref-vol">107</span>:288–94.</span> [<a href="/pubmed/18445542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18445542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.chen.2003.634">Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT. Hyperparathyroidism-jaw tumour syndrome. <span><span class="ref-journal">J Intern Med. </span>2003;<span class="ref-vol">253</span>:634–42.</span> [<a href="/pubmed/12755959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12755959</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.chen.2016.91">Chen Y, Hu DY, Wang TT, Zhang R, Dong Q, Xu ZX, Wang L, Li TJ. CDC73 gene mutations in sporadic ossifying fibroma of the jaws. <span><span class="ref-journal">Diagn Pathol. </span>2016;<span class="ref-vol">11</span>:91.</span> [<a href="/pmc/articles/PMC5034632/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5034632</span></a>] [<a href="/pubmed/27658992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27658992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.davidson.2016.32">Davidson JT, Lam CG, McGee RB, Bahrami A, Diaz-Thomas A. Parathyroid cancer in the pediatric patient. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2016;<span class="ref-vol">38</span>:32–7.</span> [<a href="/pubmed/26650250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26650250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.de_andrade.2013.662">de Andrade M, Silva-Sousa YT, Marques MF, Pontual ML, Ramos-Perez FM, Perez DE. Ossifying fibroma of the jaws: a clinicopathological case series study. <span><span class="ref-journal">Braz Dent J. </span>2013;<span class="ref-vol">24</span>:662–6.</span> [<a href="/pubmed/24474366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24474366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.domingues.2012.33">Domingues R, Tomaz RA, Martins C, Nunes C, Bugalho MJ, Cavaco BM. Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2012;<span class="ref-vol">76</span>:33–8.</span> [<a href="/pubmed/21790700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21790700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.frankraue.2011.477">Frank-Raue K, Haag C, Schulze E, Keuser R, Raue F, Dralle H, Lorenz K. CDC73-related hereditary hyperparathyroidism: five new pathogenic variants and the clinical spectrum. <span><span class="ref-journal">Eur J Endocrinol. </span>2011;<span class="ref-vol">165</span>:477–83.</span> [<a href="/pubmed/21652691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21652691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.fujikawa.1998.557">Fujikawa M, Okamura K, Sato K, Mizokami T, Tamaki K, Yanagida T, Fujishima M. Familial isolated hyperparathyroidism due to multiple adenomas associated with ossifying jaw fibroma and multiple uterine adenomyomatous polyps. <span><span class="ref-journal">Eur J Endocrinol. </span>1998;<span class="ref-vol">138</span>:557–61.</span> [<a href="/pubmed/9625369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9625369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.gill.2006.1140">Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. <span><span class="ref-journal">Am J Surg Pathol. </span>2006;<span class="ref-vol">30</span>:1140–9.</span> [<a href="/pubmed/16931959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16931959</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.guarnieri.2006.2827">Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, Minisola S, Mascia ML, D'Agruma L, Cole DE. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 pathogenic variant: implications for cancer surveillance. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:2827–32.</span> [<a href="/pubmed/16720667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16720667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.haag.2008">Haag C, Pauli S, Schulze E, Frank-Raue K, Raue F (2008) Hyperparathyroidism-jaw tumor syndrome (HPT-JT) in a 30-year-old woman with a new pathogenic variant in the HRPT2-gene. Endocr Abstr 16:P73. Abstract available <a href="http://www.hormones.gr/613/article/article.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 4-9-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.hahn.2007.5070">Hahn MA, Marsh DJ. Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. <span><span class="ref-journal">FEBS Lett. </span>2007;<span class="ref-vol">581</span>:5070–4.</span> [<a href="/pubmed/17923126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17923126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.haven.2007.370">Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H. Identification of MEN1 and HRPT2 somatic pathogenic variants in paraffin-embedded (sporadic) parathyroid carcinomas. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2007;<span class="ref-vol">67</span>:370–6.</span> [<a href="/pubmed/17555500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17555500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.haven.2000.1449">Haven CJ, Wong FK, van Dam EW, van der Juijt R, van Asperen C, Jansen J, Rosenberg C, de Wit M, Roijers J, Hoppener J, Lips CJ, Larsson C, Teh BT, Morreau H. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2000;<span class="ref-vol">85</span>:1449–54.</span> [<a href="/pubmed/10770180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10770180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.howell.2003.657">Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT. HRPT2 pathogenic variants are associated with malignancy in sporadic parathyroid tumours. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:657–63.</span> [<a href="/pmc/articles/PMC1735580/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735580</span></a>] [<a href="/pubmed/12960210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12960210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.iacobone.2009.817">Iacobone M, Masi G, Barzon L, Parzionato A, Macchi V, Ciarleglio FA, Palu G, De Caro R, Viel G, Favia G. Hyperparathyroidism jaw-tumor syndrome: a report of three large kindred. <span><span class="ref-journal">Langenbecks Arch Surg. </span>2009;<span class="ref-vol">394</span>:817–25.</span> [<a href="/pubmed/19529956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19529956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.inoue.1995.225">Inoue H, Miki H, Oshimo K, Tanaka K, Monden Y, Yamamoto A, Kagawa S, Sano N, Hayashi E, Nagayama M. Familial hyperparathyroidism associated with jaw fibroma: case report and literature review. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>1995;<span class="ref-vol">43</span>:225–9.</span> [<a href="/pubmed/7554319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7554319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.juhlin.2007.501">Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenstrom J, Forsberg L, Branstrom R, Obara T, Arnold A, Larsson C, Hoog A. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. <span><span class="ref-journal">Endocr Relat Cancer. </span>2007;<span class="ref-vol">14</span>:501–12.</span> [<a href="/pubmed/17639063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17639063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.kakinuma.1994.123">Kakinuma A, Morimoto I, Nakano Y, Fujimoto R, Ishida O, Okada Y, Inokuchi N, Fujihira T, Eto S. Familial primary hyperparathyroidism complicated with Wilms' tumor. <span><span class="ref-journal">Intern Med. </span>1994;<span class="ref-vol">33</span>:123–6.</span> [<a href="/pubmed/7912571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7912571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.krebs.2005.5015">Krebs LJ, Shattuck TM, Arnold A. HRPT2 pathogenic variantal analysis of typical sporadic parathyroid adenomas. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:5015–7.</span> [<a href="/pubmed/15956079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15956079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.kruijff.2014.426">Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenoma. <span><span class="ref-journal">Ann Surg Oncol. </span>2014;<span class="ref-vol">21</span>:426–33.</span> [<a href="/pubmed/24081804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24081804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.kutcher.2013.e175">Kutcher MR, Rigby MH, Bullock M, Trites J, Taylor SM, Hart RD. Hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">Head Neck. </span>2013;<span class="ref-vol">35</span>:E175–7.</span> [<a href="/pubmed/22302605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22302605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.lin.2008.17420">Lin L, Zhang JH, Panicker LM, Simonds WF. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2008;<span class="ref-vol">105</span>:17420–5.</span> [<a href="/pmc/articles/PMC2582266/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2582266</span></a>] [<a href="/pubmed/18987311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18987311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.mallette.1987.54">Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. <span><span class="ref-journal">Ann Intern Med. </span>1987;<span class="ref-vol">107</span>:54–60.</span> [<a href="/pubmed/3592449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3592449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.mehta.2014.1315">Mehta A, Patel D, Rosenberg A, Boufraqech M, Ellis RJ, Nilubol N, Quezado MM, Marx SJ, Simonds WF, Kebebew E. Hyperparathyroidism-jaw tumor syndrome: Results of operative management. <span><span class="ref-journal">Surgery. </span>2014;<span class="ref-vol">156</span>:1315–24.</span> [<a href="/pmc/articles/PMC4255585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4255585</span></a>] [<a href="/pubmed/25444225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25444225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.messa.2011.517">Messa P, Alfieri C, Brezzi B. Clinical utilization of cinacalcet in hypercalcemic conditions. <span><span class="ref-journal">Expert Opin Drug Metab Toxicol. </span>2011;<span class="ref-vol">7</span>:517–28.</span> [<a href="/pubmed/21361849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21361849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.mizusawa.2006.9">Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2006;<span class="ref-vol">65</span>:9–16.</span> [<a href="/pubmed/16817812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16817812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.newey.2010">Newey PJ, Bowl MR, Cranston T, Thakker RV (2010) Cell Division Cycle Protein 73 Homolog (CDC73) Pathogenic variants in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Human Pathogenic variant 31:295-307. [<a href="/pubmed/20052758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20052758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.panicker.2010.513">Panicker LM, Zhang JH, Dagur PK, Gastinger MJ, Simonds WF. Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">Endocr Relat Cancer. </span>2010;<span class="ref-vol">17</span>:513–24.</span> [<a href="/pmc/articles/PMC3098453/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3098453</span></a>] [<a href="/pubmed/20304979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20304979</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.pichardolowden.2011.602">Pichardo-Lowden AR, Manni A, Saunders BD, Baker MJ. Familial hyperparathyroidism due to a germline pathogenic variant of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. <span><span class="ref-journal">Endocr Pract. </span>2011;<span class="ref-vol">17</span>:602–9.</span> [<a href="/pubmed/21324824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21324824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.pimenta.2006.735">Pimenta FJ, Gontijo Silveira LF, Tavares GC, Silva AC, Perdigao PF, Castro WH, Gomez MV, Teh BT, De Marco L, Gomez RS. HRPT2 gene alterations in ossifying fibroma of the jaws. <span><span class="ref-journal">Oral Oncol. </span>2006;<span class="ref-vol">42</span>:735–9.</span> [<a href="/pubmed/16458039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16458039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.ravine.1993.803">Ravine D, Gibson RN, Donlan J, Sheffield LJ. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. <span><span class="ref-journal">Am J Kidney Dis. </span>1993;<span class="ref-vol">22</span>:803–7.</span> [<a href="/pubmed/8250026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8250026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.rekik.2010.121">Rekik N, Ben Naceur B, Mnif M, Mnif F, Mnif H, Boudawara T, Abid M. Hyperparathyroidism-jaw tumor syndrome: a case report. <span><span class="ref-journal">Ann Endocrinol (Paris). </span>2010;<span class="ref-vol">71</span>:121–6.</span> [<a href="/pubmed/19942209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19942209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.rozenblattrosen.2005.612">Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M. The parafibromin tumor suppressor protein is part of a human Paf1 complex. <span><span class="ref-journal">Mol Cell Biol. </span>2005;<span class="ref-vol">25</span>:612–20.</span> [<a href="/pmc/articles/PMC543415/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC543415</span></a>] [<a href="/pubmed/15632063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15632063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.sato.2016.91">Sato T, Muroya K, Hanakawa J, Yamashita S, Nozawa K, Masudo K, Yamakawa T, Asakura Y, Hasegawa T, Adachi M. Potential utility of cinacalcet as a treatment for CDC73-related primary hyperparathyroidism: a case report. <span><span class="ref-journal">Clin Pediatr Endocrinol. </span>2016;<span class="ref-vol">25</span>:91–8.</span> [<a href="/pmc/articles/PMC4965508/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4965508</span></a>] [<a href="/pubmed/27507909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27507909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.shattuck.2003.1722">Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A. Somatic and germ-line pathogenic variants of the HRPT2 gene in sporadic parathyroid carcinoma. <span><span class="ref-journal">NEJM. </span>2003;<span class="ref-vol">349</span>:1722–9.</span> [<a href="/pubmed/14585940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14585940</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.silverberg.2007.3803">Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:3803–8.</span> [<a href="/pubmed/17666472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17666472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.simonds.2002.1">Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. <span><span class="ref-journal">Medicine (Baltimore). </span>2002;<span class="ref-vol">81</span>:1–26.</span> [<a href="/pubmed/11807402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11807402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.simonds.2004.96">Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline pathogenic variant in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:96–102.</span> [<a href="/pubmed/14715834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14715834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.siu.2011.695">Siu WK, Law CY, Lam CW, Mak CM, Wong GW, Ay Ho, Ho KY, Loo KT, Chiu SC, Chow LT, Tong SF, Chan AY. Novel nonsense CDC73 pathogenic variants in Chinese patients with parathyroid tumors. <span><span class="ref-journal">Fam Cancer. </span>2011;<span class="ref-vol">10</span>:695–9.</span> [<a href="/pubmed/21732217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21732217</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.starker.2012.44">Starker LF, Akerstrom T, Long WE, Delgado-Verdugo A, Donovan P, Udelsman R, Lifton RP, Carling T. Frequent germ-line pathogenic variants of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. <span><span class="ref-journal">Horm Cancer. </span>2012;<span class="ref-vol">3</span>:44–51.</span> [<a href="/pubmed/22187299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22187299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.szab_.1995.944">Szab&#x000f3; J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, Leppert MF, Heath H. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. <span><span class="ref-journal">Am J Hum Genet. </span>1995;<span class="ref-vol">56</span>:944–50.</span> [<a href="/pmc/articles/PMC1801214/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1801214</span></a>] [<a href="/pubmed/7717405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7717405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.tan.2004.6629">Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. <span><span class="ref-journal">Clin Cancer Res. </span>2004;<span class="ref-vol">10</span>:6629–37.</span> [<a href="/pubmed/15475453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15475453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.tan.2004.895">Tan MH, Teh BT. Renal neoplasia in the hyperparathyroidism-jaw tumor syndrome. <span><span class="ref-journal">Curr Mol Med. </span>2004;<span class="ref-vol">4</span>:895–7.</span> [<a href="/pubmed/15579037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15579037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.teh.1996.4204">Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, Yap A, Epstein M, Heath H 3rd, Cameron D, Larsson C. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1996;<span class="ref-vol">81</span>:4204–11.</span> [<a href="/pubmed/8954016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8954016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.van_der_tuin.2017.4534">van der Tuin K, Tops C, Adank MA, Cobben JM, Hamdy N, Jongmans MC, Menko FH, van Nesselrooij B, Netea-Maier RT, Oosterwijk JC, Valk GD, Wolffenbuttel B, Hes FJ, Morreau H. CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2017;<span class="ref-vol">102</span>:4534–40.</span> [<a href="/pubmed/29040582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29040582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.villablanca.2004.e32">Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG, Larsson C. Germline and de novo pathogenic variants in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:e32.</span> [<a href="/pmc/articles/PMC1735713/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735713</span></a>] [<a href="/pubmed/14985403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14985403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.wang.2010.1694">Wang CY, Wang O, Nie M, Zhao DC, Xia WB, Li M, Guan H, Mend XW, Xing XP. Clinical and molecular genetic analyses for a sporadic parathyroid carcinoma. <span><span class="ref-journal">Zhonghua Yi Xue Za Zhi. </span>2010;<span class="ref-vol">90</span>:1694–7.</span> [<a href="/pubmed/20979880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20979880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.warner.2004.155">Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Birdsey P, Mackenzie E, Teh BT, Prins JB, Cardinal J. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:155–60.</span> [<a href="/pmc/articles/PMC1735699/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735699</span></a>] [<a href="/pubmed/14985373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14985373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.warner.2006.e12">Warner JV, Nyholt DR, Busfield F, Epstein M, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Teh BT, Prins JB, Cardinal JW. Familial isolated hyperparathyroidism is linked to a 1.7 Mb region on chromosome 2p13.3-14. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:e12.</span> [<a href="/pmc/articles/PMC2563254/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563254</span></a>] [<a href="/pubmed/16525030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16525030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.woodard.2005.1272">Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:1272–6.</span> [<a href="/pubmed/15580289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15580289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.yang.2010.382">Yang Y-J, Han J-W, Youn HD, Cho E-J. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. <span><span class="ref-journal">Nucleic Acids Research. </span>2010;<span class="ref-vol">38</span>:382–90.</span> [<a href="/pmc/articles/PMC2811029/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2811029</span></a>] [<a href="/pubmed/19906718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19906718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hrpt2.REF.zhao.2007.3440">Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W, Moch H. Sporadic human renal tumors display frequent allelic imbalances and novel pathogenic variants of the HRPT2 gene. <span><span class="ref-journal">Oncogene. </span>2007;<span class="ref-vol">26</span>:3440–9.</span> [<a href="/pubmed/17130827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17130827</span></a>]</div></li></ul></div></div><div id="hrpt2.Chapter_Notes"><h2 id="_hrpt2_Chapter_Notes_">Chapter Notes</h2><div id="hrpt2.Author_History"><h3>Author History</h3><p>Maria E Cabanillas, MD; University of Texas, Houston (2008-2012)<br />Mimi I Hu, MD (2012-present)<br />Samuel M Hyde, MMSc, CGC (2018-present) <br />Michelle A Jackson, MS, CGC; University of Texas MD Anderson Cancer Center (2015-2018)<br />Jack W Martin, MD; University of Texas MD Anderson Cancer Center (2008-2015)<br />Nancy D Perrier, MD, FACS (2008-present)<br />Thereasa A Rich, MS, CGC (2008-present)<br />Steven G Waguespack, MD (2008-present)</p></div><div id="hrpt2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>26 April 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 January 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 December 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>12 August 2008 (tar) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK3789</span><span class="label">PMID: <a href="/pubmed/20301744" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301744</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/catsper-mi/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cdk13-dis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK3789&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK3789/?report=reader">PubReader</a></li><li><a href="/books/NBK3789/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK3789" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK3789" style="display:none" title="Cite this Page"><div class="bk_tt">Hyde SM, Rich TA, Waguespack SG, et al. CDC73-Related Disorders. 2008 Dec 31 [Updated 2018 Apr 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK3789/pdf/Bookshelf_NBK3789.pdf">PDF version of this page</a> (500K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hrpt2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hrpt2.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#hrpt2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hrpt2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hrpt2.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hrpt2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hrpt2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hrpt2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hrpt2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hrpt2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hrpt2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hrpt2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=79577[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CDC73</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK3789+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1459406" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1459406" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1459406" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1459406" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25511968" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.</a><span class="source">[J Oral Maxillofac Surg. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Parfitt J, Harris M, Wright JM, Kalamchi S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Oral Maxillofac Surg. 2015 Jan; 73(1):194.e1-9. Epub 2014 Sep 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301710" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple Endocrine Neoplasia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple Endocrine Neoplasia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Giusti F, Marini F, Brandi ML. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20052758" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.</a><span class="source">[Hum Mutat. 2010]</span><div class="brieflinkpop offscreen_noflow">Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Newey PJ, Bowl MR, Cranston T, Thakker RV. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mutat. 2010 Mar; 31(3):295-307. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28774260" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.</a><span class="source">[BMC Med Genet. 2017]</span><div class="brieflinkpop offscreen_noflow">Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Guarnieri V, Seaberg RM, Kelly C, Jean Davidson M, Raphael S, Shuen AY, Baorda F, Palumbo O, Scillitani A, Hendy GN, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Med Genet. 2017 Aug 3; 18(1):83. Epub 2017 Aug 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28288139" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.</a><span class="source">[Oncogene. 2017]</span><div class="brieflinkpop offscreen_noflow">Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Walls GV, Stevenson M, Lines KE, Newey PJ, Reed AAC, Bowl MR, Jeyabalan J, Harding B, Bradley KJ, Manek S, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Oncogene. 2017 Jul 13; 36(28):4025-4036. Epub 2017 Mar 13.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301744" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301744" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419ea39a66ee2ba62b0d0">CDC73-Related Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">CDC73-Related Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE899CB9E04121910000000003F101B2&amp;ncbi_session=CE899CB9E0419EA1_1009SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK3789%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK3789&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK3789/&amp;ncbi_pagename=CDC73-Related Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE899CB9E0419EA1_1009SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>